A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.

Alexander E Drilon, Vivek Subbiah, Geoffrey R Oxnard, Todd Michael Bauer, Vamsidhar Velcheti, Nehal J Lakhani, Benjamin Besse, Keunchil Park, Jyoti D Patel, Maria E Cabanillas, Melissa Lynne Johnson, Karen L Reckamp, Valentina Boni, Herbert HF Loong, Martin Schlumberger, Ben Solomon, Scott Cruickshank, Stephen M Rothenberg, Manisha H Shah, Lori J Wirth